China Biologic Products Appoints Director of Research and D...(expressions involve known and unknown ri...)

Date:9/9/2009

expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:

    China Biologic Products, Inc.
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:  http://www.chinabiologic.com

    Investor Relations Contact:

    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915 (NY office)
     Email: crocker.coulson@ccgir.com

     Mr. Gary Chin
     Tel:   +1-646-213-1909
     Web:  http://www.ccgirasia.com

'/>"/>

SOURCE China Biologic Products, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
2. Fauve Intertrade Signs Major Energy Contracts in China
3. China Biologic Products to Participate in the Rodman & Renshaw Annual Global Investment Conference
4. China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes
5. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
6. AOBOs Products Included in Chinas Essential Drug List
7. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
8. China Medical Technologies to Announce Unaudited Financial Results for the Fourth Fiscal Quarter and Fiscal Year ended March 31, 2009 and the First Fiscal Quarter ended June 30, 2009 on September 1, 2009
9. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
10. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
11. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results